NEW YORK – Molecular diagnostic assay developer SpeeDx plans to expand into host-response biomarker testing with a single biomarker called interferon alpha inducible protein 27, or IFI27. The Sydney, Australia-based firm expects to develop the biomarker into a PCR assay called Insignia intended for triaging COVID-19 patients in 2021, and is also developing its own SARS-CoV-2 tests.
Changes in gene expression in response to infection can differ depending on whether a person is infected by a virus or bacteria, in some cases in anticipation of symptoms.